

Biolnvent gets IND nod for Phase I/IIa trial of anti-FcγRIIB antibody

04 July 2019 | News

The anti-FcγRIIB antibody is part of Biolnvent's FcγRIIB-targeting program, which has emerged from its F.I.R.S.T™ platform technology



Biolnvent International AB (BINV) has received authorization from the U.S. Food and Drug Administration (FDA) to proceed with an Investigational New Drug (IND) application for a Phase I/IIa clinical trial of an immune-modulatory anti-FcγRIIB antibody in combination with an anti-PD1 antibody in solid tumors.

The anti-FcγRIIB antibody is part of Biolnvent's FcγRIIB-targeting program, which has emerged from its F.I.R.S.T™ platform technology, which simultaneously identifies both targets and high-quality antibodies that bind to them, generating potentially promising new drug candidates. The Phase I/IIa trial is planned to be carried out in the U.S. and the EU.

“This antibody may improve the therapeutic efficacy of anti-PD1 targeting antibodies, and this study will explore the potential to improve responses observed in the treatment of solid cancers. Progressing this first in class monoclonal antibody into clinical development further reinforces the productivity of Biolnvent's platform, which continues to produce novel cancer therapies which not only broaden our own pipeline, but also add further licensing and partnering opportunities,” says Biolnvent's CEO Martin Welschhof.

The Phase I/IIa study is one of four new clinical programs in solid cancers that the Company intends to initiate. These also include BI-1607 (an anti-FcγRIIB antibody) in combination with a checkpoint inhibitor; BI-1808 (an anti-TNFR2 antibody); and the collaboration with Transgene to develop oncolytic viruses encoding a validated anti-CTLA-4 antibody.